Treace Medical Concepts, Inc. (TMCI)
| Market Cap | 297.21M -31.7% |
| Revenue (ttm) | 205.31M -4.0% |
| Net Income | -59.52M |
| EPS | -0.93 |
| Shares Out | 65.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 258,331 |
| Open | 4.460 |
| Previous Close | 4.450 |
| Day's Range | 4.370 - 4.620 |
| 52-Week Range | 1.170 - 7.780 |
| Beta | 1.40 |
| Analysts | Hold |
| Price Target | 5.50 (+20.35%) |
| Earnings Date | Aug 7, 2026 |
About TMCI
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percupla... [Read more]
Financial Performance
In 2025, Treace Medical Concepts's revenue was $212.69 million, an increase of 1.59% compared to the previous year's $209.36 million. Losses were -$59.00 million, 5.85% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TMCI stock is "Hold." The 12-month stock price target is $5.5, which is an increase of 20.35% from the latest price.
News
Treace Medical Concepts Earnings Call Transcript: Q2 2026
Revenue declined 4% year-over-year in Q2 2026 to $45.4M, but case volume growth accelerated to high single digits, driven by new product adoption and market share gains. Full-year guidance was raised, with expectations for sequential revenue growth and a strong Q4.
Treace Medical Concepts Earnings release: Q2 2026
Treace Medical Concepts released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Treace Medical Concepts Quarterly report: Q2 2026
Treace Medical Concepts has published its Q2 2026 quarterly earnings report on August 7, 2026.
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
PONTE VEDRA, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical price target raised to $4 from $2 at Truist
Truist raised the firm’s price target on Treace Medical (TMCI) to $4 from $2 and keeps a Hold rating on the shares as part of a broader research note previewing…
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI) against...
Treace Medical Concepts Transcript: Sidoti Small-Cap Virtual Investor Conference
Strong market share gains and a broadened product portfolio have driven accelerated procedure volumes and doubled market penetration to 8% in 2025. Financial performance improved with significant reductions in EBITDA loss and cash usage, while new minimally invasive technologies and expanded sales efforts position the company for continued growth.
Treace Medical announces first surgical case with HyperPlate XM implant
Treace Medical (TMCI) Concepts announced the successful completion of the first case utilizing its HyperPlate XM Dynamic Compression Locking Implant. “The launch of HyperPlate XM implants marks anothe...
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base Ne...
Treace to Present at the Sidoti Small Cap Conference
PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical Concepts Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, all of which passed. A 4.7% average salary increase for non-executives was disclosed during the Q&A. Final voting results will be filed with the SEC.
Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI). The investigation focuses on ...
Treace Medical Concepts Earnings Call Transcript: Q1 2026
Q1 2026 saw a 10% revenue decline due to lower-priced product mix, but case volumes grew mid-single digits and gross margins remained strong. New product adoption is accelerating, with guidance reaffirmed for improved performance and revenue growth in Q4 2026.
Treace Medical Concepts Earnings release: Q1 2026
Treace Medical Concepts released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Treace Medical Concepts Quarterly report: Q1 2026
Treace Medical Concepts has published its Q1 2026 quarterly earnings report on May 8, 2026.
Treace Medical Concepts Reports First Quarter 2026 Financial Results
PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical...
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgic...
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
New portfolio addition taps into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition tap...
Treace Medical Concepts Proxy statement: Proxy filing
Treace Medical Concepts filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Treace Medical Concepts Proxy statement: Proxy filing
Treace Medical Concepts filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Treace Medical price target lowered to $2 from $3 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Treace Medical (TMCI) to $2 from $3 and keeps a Hold rating on the shares. The company’s Q4 saw negative…
Treace Medical price target lowered to $2.25 from $2.50 at UBS
UBS lowered the firm’s price target on Treace Medical (TMCI) to $2.25 from $2.50 and keeps a Neutral rating on the shares.
Treace Medical price target lowered to $7 from $7.50 at Lake Street
Lake Street lowered the firm’s price target on Treace Medical (TMCI) to $7 from $7.50 and keeps a Buy rating on the shares. Treace’s Q4 was slightly favorable to preliminary…